A Proliferation‐inducing Ligand (APRIL) is Expressed by Astrocytes and is Increased in Multiple Sclerosis
Open Access
- 14 December 2006
- journal article
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 65 (1) , 92-98
- https://doi.org/10.1111/j.1365-3083.2006.01867.x
Abstract
A proliferation-inducing ligand (APRIL) is a newly described member of the tumour necrosis factor (TNF) superfamily that was first identified as a factor favouring tumorigenesis. APRIL is also important for several immune functions, including B-cell survival. Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous system (CNS) that is commonly diagnosed in early adulthood. Several TNF superfamily members have been identified in brains of patients with MS, although their exact function within the CNS is presently unknown. To investigate whether APRIL is expressed in the CNS, we studied APRIL protein expression by immunohistochemistry in MS patients and controls. Morphologically, APRIL-positive cells appeared to be astrocytes. A two-colour immunohistochemistry revealed that APRIL expression was cytoplasmic, granular and restricted to GFAP-positive cells. Conversely, HLA class II-positive microglial cells were negative for APRIL expression. APRIL-positive cells were fewer in brains of controls compared with those with MS. We further corroborated our findings by studying APRIL protein expression in several glioblastoma cell lines, and found APRIL to be expressed by most cell lines analysed. APRIL's binding partner syndecan-1 (CD138) was detected in brains of neither MS nor control patients. Furthermore, B cells were detectable in the brain of one of five patients with MS. We conclude that APRIL is expressed by reactive astrocytes in MS and may be of relevance in gliotic scar formation.Keywords
This publication has 33 references indexed in Scilit:
- An APRIL to remember: novel TNF ligands as therapeutic targetsNature Reviews Drug Discovery, 2006
- Raised serum APRIL levels in patients with systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2005
- Identification of proteoglycans as the APRIL-specific binding partnersThe Journal of Experimental Medicine, 2005
- Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferationCell Death & Differentiation, 2005
- Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2004
- BAFF and APRIL: A Tutorial on B Cell SurvivalAnnual Review of Immunology, 2003
- BAFF-R, a Newly Identified TNF Receptor That Specifically Interacts with BAFFScience, 2001
- An Essential Role for BAFF in the Normal Development of B Cells Through a BCMA-Independent PathwayScience, 2001
- Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseasesArthritis & Rheumatism, 2001
- Axonal Transection in the Lesions of Multiple SclerosisNew England Journal of Medicine, 1998